Olinvacimab
Based on 1 Customer Validation
Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer.
For research use only. We do not sell to patients.
- Purity: ≥95.0%
- CAS No.: 2095504-49-5
- Molecular Weight:148.16 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All VEGFR Isoforms
More
Biological Activity
IgG1-Vlambda-Ckappa
Human
VEGFR2/KDR/CD309
Olinvacimab (0-1000 nM) inhibits binding of VEGF to its receptor KDR with a Kd value of 0.23 nM[1]. Olinvacimab inhibits VEGF-165, VEGF-C and VEGF-D binding to VEGFR-2 with IC50 values of 8.7, 6.3 and 7.0 nM, respectively[1]. Olinvacimab (0.5-30 μg/mL; 30 min) inhibits the phosphorylation of VEGFR-2/KDR and ERK[1]. Olinvacimab (1, 15 and 20 mg/mL; 30 min) inhibits VEGF-induced proliferation of HUVEC[1]. Olinvacimab (20 mg/mL; 30 min) inhibits VEGF-stimulated HUVEC migration[1]. Olinvacimab (5, 10 and 20 μg; 20 h) dose-dependently inhibits tube formation and disorders tubular structures[1]. Olinvacimab (1 and 20 μg; 6 d) inhibits hVEGF165-induced rat aortic ring vessel sprouting[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human umbilical vein endothelial cell (HUVEC) line
-
Concentration:0.5, 1, 5, 10, 20 and 30 μg/mL
-
Incubation Time:30 min
-
Result:Inhibited VEGF-induced phosphorylation of VEGFR-2 and ERK (downstream signaling molecule) in HUVECs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Matrigel-implanted nude mice model[1]
-
Dosage:100 ng
-
Administration:Subcutaneous injection; 100 ng, once
-
Result:Inhibited the neovascularization induced by hVEGF165.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-Vlambda-Ckappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 HUVEC cells with Olinvacimab (HY-P99768, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 2095504-49-5
-
Appearance Liquid
-
Molecular Weight 148.16 kDa
-
Color Colorless to light yellow
-
SMILES
[Olinvacimab]
-
Synonyms
TTAC-0001; Tanibirumab
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz